The company

Rosemont Pharmaceuticals is the UK’s leading liquid pharmaceuticals business. Its portfolio of over 130 oral liquid medicines includes 70 licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.

The Inflexion difference

With substantial experience in successfully executing carve-outs, Inflexion will draw upon its healthcare expertise to establish Rosemont as a standalone business and invest further in innovation and new product development. Inflexion will also support the geographical expansion of the business.  

We’re extremely pleased to be able to announce this exciting new chapter for Rosemont. As a very well established and respected supplier in the industry, we look forward to working with Inflexion and drawing on their relevant experience in our sector to continue to invest in the business and expand our quality product range.

Howard Taylor,

CEO, Rosemont Pharmaceuticals